explore -WSS

explore

author：comprehensive 2025-09-28 23:47:04 - browse：7437

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： How to use technology to prevent future drug shortages

WSS

Industry veterans launch new biotech VC with $310M

Medicare Advantage proposed rates disappoint insurers

Private equity deals in Medicare Advantage declines

Police still searching for prisoner who escaped from NYC hospital

Gilead might be held responsible for not developing a drug

Biden report: The neurospychology of memory and aging

leisure time

explore

focus

Guidelines to prevent youth baseball injuries need more muscle

Biogen Alzheimer’s drug launch off to slow start

Guidelines to prevent youth baseball injuries need more muscle

Private equity deals in Medicare Advantage declines

What does generative AI mean for health care? We asked experts

Readout LOUD podcast: How biotech is using artificial intelligence

Moonlake's readout produced a cash windfall. Risks remain

Medicare Advantage proposed rates disappoint insurers

Apple is now the first public company to be valued at $3 trillion

Medicare threatens to cut off funding for HCA's Mission hospital

hotspot

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

Biogen Alzheimer’s drug launch off to slow start

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Robert F. Kennedy is pitching centrism on health, even on abortion

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

leisure time

focus

leisure time

focus